G Curigliano MD PhD

@curijoey

Giuseppe Curigliano, MD, PhD, Associate Professor at University of Milan and Head of Phase I Division at IEO, ESMO Council Member, Tweets are my own

Milan, Italy
Vrijeme pridruživanja: lipanj 2015.

Tweetovi

Blokirali ste korisnika/cu @curijoey

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @curijoey

  1. prije 11 sati

    Pan-Cancer Analysis of Whole Genomes. A collection of research and related content from the ICGC/TCGA consortium on whole-genome sequencing and integrative analysis of cancer

    Poništi
  2. proslijedio/la je Tweet
    prije 21 sat

    China National Health Commission reports latest update for 2/5 - Confirmed cases +3694: 24324➡️28018 - Suspected cases +5328: 23260➡️24702 - Severe cases +640: 3219➡️3859 - Deaths +73: 490➡️563 - Discharged +261: 892➡️1153

    Poništi
  3. proslijedio/la je Tweet
    4. velj
    Poništi
  4. proslijedio/la je Tweet
    4. velj

    : 'We need to fight for and state that no limitations cannot be challenged… and create more equity in the future in the way that we treat worldwide, delivering to patients optimal cancer care'

    Poništi
  5. proslijedio/la je Tweet
    3. velj

    : ' and access to the best cancer care are going to be key.' ESMO Past President Josep Tabernero on the priorities that need to be addressed in the fight against

    Poništi
  6. proslijedio/la je Tweet
    2. velj

    : While revolutionary advances have been achieved in care, a lot still needs to be done in the fight for a world free from cancer. Watch , ESMO President-Elect, speak about the Society's priorities in the fight against the disease

    Poništi
  7. 2. velj

    An hospital in 10 days. Virus isolated in 15 days. Medical science and care are a marvel!

    Poništi
  8. 2. velj

    How the Brain Can Rewire Itself After Half of It Is Removed

    Poništi
  9. 1. velj

    With our friend as coauthor supported by an fellowship!

    Poništi
  10. 31. sij

    The 2020 ESMO Awards: There's still time to tell us who is making a difference in the world of and should be recognised for their excellence - nominate your candidates before 16/2

    Poništi
  11. proslijedio/la je Tweet
    15. sij

    Our new review of big data in healthcare: We define big data in medicine and the various axes of medical data, describe data-generation processes, considerations for constructing longitudinal cohorts, data-analysis methods, and challenges

    Prikaži ovu nit
    Poništi
  12. proslijedio/la je Tweet
    14. stu 2019.

    Drug resistance is driven by tumor heterogeneity, tumor burden, tumor growth, tumor micro-environment, physical barriers, therapeutic pressure, etc. Check out this superb review by

    Poništi
  13. proslijedio/la je Tweet
    21. sij
    Poništi
  14. proslijedio/la je Tweet
    25. sij

    A new dedicated issue on in (via ) My bit on the big potential impact: Care is the human bond, and we’ve largely lost that. We’ve got to get it back.

    Poništi
  15. 26. sij
    Poništi
  16. proslijedio/la je Tweet
    22. sij

    Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

    Poništi
  17. 20. sij

    Breast implant-associated anaplastic large cell lymphoma: A comprehens...

    Poništi
  18. proslijedio/la je Tweet
    18. sij

    📣 New ESMO consensus recommendations on 'Management of cardiac disease in pts throughout oncological treatment' 👉 Read more on the prevention, detection & treatment of

    Poništi
  19. 18. sij
    Poništi
  20. proslijedio/la je Tweet
    18. sij

    Just out by our amazing 🚨Colleagues & team. The guidelines📖for the management of cardiac❤️disease in patients. Kudos to all the authors involved 🙌

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·